Botulinum toxin type A + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cerebrovascular Accident
Conditions
Cerebrovascular Accident, Muscle Spasticity
Trial Timeline
Nov 1, 2004 → Jul 20, 2006
NCT ID
NCT00216411About Botulinum toxin type A + Placebo
Botulinum toxin type A + Placebo is a approved stage product being developed by Ipsen for Cerebrovascular Accident. The current trial status is completed. This product is registered under clinical trial identifier NCT00216411. Target conditions include Cerebrovascular Accident, Muscle Spasticity.
What happened to similar drugs?
4 of 6 similar drugs in Cerebrovascular Accident were approved
Approved (4) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03569098 | Phase 2 | Completed |
| NCT03598777 | Phase 2 | Terminated |
| NCT02493946 | Phase 3 | Completed |
| NCT02353871 | Phase 3 | Completed |
| NCT02321436 | Approved | Completed |
| NCT01753310 | Phase 3 | Completed |
| NCT01249417 | Phase 3 | Completed |
| NCT01357980 | Phase 2 | Completed |
| NCT01249404 | Phase 3 | Completed |
| NCT00578097 | Phase 2 | Terminated |
| NCT00257660 | Phase 3 | Completed |
| NCT00447876 | Phase 2/3 | Completed |
| NCT00216411 | Approved | Completed |
| NCT00234546 | Approved | Completed |
Competing Products
14 competing products in Cerebrovascular Accident
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM872 (zonampanel) | Astellas Pharma | Phase 2 | 35 |
| donepezil hcl | Eisai | Phase 3 | 40 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 43 |
| ONO-2506 | Ono Pharmaceutical | Phase 2/3 | 30 |
| Abciximab | Eli Lilly | Phase 3 | 32 |
| atomoxetine + Stimulants | Eli Lilly | Pre-clinical | 26 |
| ticagrelor + ASA + Placebo+ASA | AstraZeneca | Approved | 43 |
| Valsartan | Novartis | Pre-clinical | 18 |
| Atorvastatin | Pfizer | Approved | 43 |
| Rivaroxaban | Bayer | Pre-clinical | 19 |
| Darolutamide (BAY1841788) + Enzalutamide | Bayer | Phase 1 | 26 |
| Atorvastatin 20mg | Brain Biotech | Approved | 40 |
| Autologous bone marrow mononuclear cell transplantation | Brain Biotech | Phase 1 | 11 |
| Roflumilast Oral Tablet | Brain Biotech | Phase 2 | 25 |